Information on Gleevec (Imatinib Mesylate)
Gleevec is approved to treat a rare cancer called Chronic Myeloid Leukemia (CML).
On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.
Gleevec is approved to treat a rare cancer called Chronic Myeloid Leukemia (CML).